Forward by our Assistant Editor – Research from UBC’s School of Biomedical Engineering have found out that a cancer drug called a colony-stimulating factor 1 receptor (CSF1R) inhibitor, may treat people with muscular dystrophy. There are many forms of muscular dystrophy, a severe genetic disorder which leads to muscle weakness and loss, which is usually diagnosed when a child is 3 to 6 years old. This illness decreases life expectancies by impacting heart and lung function. There is no current cure. However, CSF1R is slowing down the deterioration of the disease and helping muscular dystrophy patients keep their mobility for longer.
By Khaleel Chima - Assistant Editor - Lead Roving Reporter – Ability Today
Researchers at UBC’s School of Biomedical Engineering have discovered that an existing cancer drug could have potential as a treatment for muscular dystrophy.
The researchers found that the drug — known as a colony-stimulating factor 1 receptor (CSF1R) inhibitor — helped slow the progress of Duchenne muscular dystrophy in mice by increasing the resiliency of muscle fibres.
The findings were published today in Science Translational Medicine.
Read more at: https://news.ubc.ca/2022/06/29/cancer-drug-shows-potential-as-treatment-for-muscular-dystrophy/